Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetylcysteine for Carbapenem-Resistant Klebsiella VAP
NCT07097727Phase 1Completed
- Sponsor
- Tanta University
- Start
- Oct 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial in ventilator-associated pneumonia (VAP) comparing Acetylcysteine + Antibiotics with Placebo + Antibiotics (2 arms). Primary endpoint: Clinical Pulmonary Infection Score at 14 days. Started Oct 2023; status: completed.
02
Drugs
acetylcysteine
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT07097727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07097727.